Created in 1961 and based in Washington DC (USA), Advanced BioScience Laboratories, Inc. is an unlisted company wholly owned by
ABL, Inc. is dedicated to research and development in infectious diseases and, in particular, AIDS since the discovery of the first retroviruses 25 years ago. With ABL, Inc., Institut Mérieux has the potential for cutting edge research in virology, and a very large network and expertise in the fight against AIDS.
ABL, Inc. has more than 40 years of expertise in the following areas:
Its recognized expertise allows it in particular to provide, for the US National Institutes of
Health, management of major development programs focusing on AIDS: vaccinal and immunotherapeutic
approaches and prevention with microbicides.
In parallel with this work on HIV, the NIH has awarded ABL, Inc. several programs for management of
pre-clinical development of vaccines against different infectious diseases.
ABL, Inc. is also broadening its research targets to infectious diseases other than HIV, with programs focused on infectious agents that cause major public health problems worldwide: influenza, SARS, Streptococcus Mutans, Candida Albicans, norovirus.
120 people are mobilized in these programs.
ABL, Inc. also has production capacities meeting standards for Good Manufacturing Practices.